Form 4: Nurix Therapeutics CFO Reports Routine RSU Vesting and Tax-Related Stock Sale
Insider Transaction Report
Nurix Therapeutics' Chief Financial Officer, Hans van Houte, reported the vesting of restricted stock units and a non-discretionary sale of shares to cover tax obligations.
Summary
- Hans van Houte, Chief Financial Officer of Nurix Therapeutics, Inc. (NRIX), reported multiple transactions on July 30, 2025, related to his equity compensation.
- Acquired a total of 11,494 shares of common stock through the vesting of restricted stock units (RSUs) at an exercise price of $0.
- Disposed of 4,304 shares of common stock at a weighted average sale price of $12.011, with prices ranging from $11.78 to $12.315.
- The sale of shares was mandated by the Issuer's equity incentive plans to cover tax withholding obligations in connection with the RSU vesting and was not a discretionary trade.
- Following these transactions, Hans van Houte beneficially owns 40,914 shares of common stock directly.
- Remaining derivative securities include 5,773, 6,000, 26,250, and 31,442 restricted stock units, which represent contingent rights to receive one share of common stock each upon vesting.
Sentiment
Score: 5
Explanation: The filing reports routine insider transactions related to equity compensation, specifically the vesting of restricted stock units and a non-discretionary 'sell to cover' transaction for tax purposes. This is a standard event and does not indicate a change in company fundamentals or management's discretionary view of the stock.
Positives
- The vesting of restricted stock units indicates the continued compensation and retention of a key executive, aligning management's interests with shareholders.
- The 'sell to cover' transaction is a non-discretionary event, which does not signal a lack of confidence in the company by the reporting person.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
This filing details a routine insider transaction related to executive equity compensation, which is a common practice across various industries to incentivize and retain key personnel. It does not provide insights into broader industry trends or competitive dynamics.
Related Party Transactions
- The vesting of restricted stock units represents a form of equity compensation granted by the Issuer to its Chief Financial Officer, which is a related party transaction.
Stakeholder Impact
- Shareholders: Minimal direct impact, as the 'sell to cover' transaction is a routine event and does not reflect a discretionary sale by management. The conversion of RSUs to common stock slightly increases the outstanding share count.
Next Steps
- Continued vesting of remaining restricted stock units according to their respective schedules (quarterly over three or four years).
Key Dates
| Date | Description |
|---|---|
| 04/30/2022 | First quarterly increment vesting for 2,886 restricted stock units. |
| 07/30/2023 | First quarterly increment vesting for 2,000 restricted stock units. |
| 07/30/2024 | First quarterly increment vesting for 3,750 restricted stock units. |
| 07/30/2025 | Date of reported RSU vesting and stock sale transactions; First quarterly increment vesting for 2,858 restricted stock units. |
Keywords
Nurix Therapeutics, NRIX, Form 4, Insider Transaction, RSU Vesting, Stock Sale, Chief Financial Officer, Equity Compensation, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.